| Aug 20 |
Mirum Banks on Livmarli, Overdependence a Concern
|
| Aug 20 |
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
|
| Aug 19 |
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
|
| Aug 19 |
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
|
| Aug 16 |
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
|
| Aug 12 |
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
|
| Aug 12 |
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
|
| Aug 9 |
Novavax Lags on Q2 Earnings & Sales, Cuts '24 Outlook
|
| Aug 9 |
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 9 |
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
|
